Request FREE sample PDF ![PDF](https://www.businessresearchinsights.com/assets/img/popup-form/PDF.svg)
Pharmacy benefit management market
ATORVASTATIN CALCIUM MARKET REPORT OVERVIEW
The global atorvastatin calcium market size is expected to be USD 236.8 million in 2022 and is expected to reach USD 454.06 million in 2031, at a CAGR of 7.5% during the forecast period.
Atorvastatin is a statin drug used to treat abnormal cholesterol levels and prevent cardiovascular disease in those at high risk. It is marketed under the trade names Lipitor and others. Statins are the first line of defense against cardiovascular disease. It is consumed orally. A prescription drug called Lipitor that decreases blood triglycerides and LDL cholesterol and has the potential to raise HDL cholesterol is made from the pharmaceutical raw material atorvastatin calcium. Typically, calcium atorvastatin comes as a white powder.
The increasing use of atorvastatin in the treatment of cardiovascular infections has largely benefited the atorvastatin calcium market. The rise of dyslipidemia in China presents prospects for market expansion. It is anticipated that limiting the negative effects of atorvastatin on prosperity will maintain atorvastatin calcium market growth. One of the main factors influencing the market is the rise in the prevalence of hypercholesterolemia. Additionally, a rise in the use of combination therapies, which combine statins with additional cholesterol-lowering drugs like ezetimibe, is anticipated to improve the market growth.
COVID-19 Impact: Halt on Manufacturing Operations to Slower Market Growth
The global COVID-19 pandemic has been unprecedented and staggering, with atorvastatin calcium experiencing lower-than-anticipated/higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the atorvastatin calcium market growth and demand returning to pre-pandemic levels once the pandemic is over.
The outbreak of COVID-19 had a negative impact on several markets. By driving up the price of essential fixings, the Covid outbreak and its expansion have started to affect a sizable portion of the nation. Penicillin and nutrition are currently twice as expensive. Paracetamol now costs more money. Another significant impact is the disruptions caused by expanded processing plant closures for a pharma company. In the event that the pandemic spreads earlier than expected, medicine supplies, raw drug ingredients, and other synthetics may be depleted, leading to shortages.
LATEST TRENDS
"Increasing Adoption in Healthcare to Boost Market Growth"
Atorvastatin (AVS) is a lipid-lowering medication that inhibits 3-hydroxy-3-methylglutaryl-coenzyme in a competitive, selective manner. A reductase that catalysis the rate-limiting step in the synthesis of cholesterol, the conversion of HMG-CoA to mevalonate. Low-density lipoprotein (bad cholesterol) and triglyceride levels are reduced by AVS while high-density lipoprotein levels are increased (good cholesterol). In persons with type II diabetes and coronary heart disease, VS is frequently used to treat excessive cholesterol and to reduce their risk of heart attack, myocardial infarction, angina, stroke, and other heart issues.
ATORVASTATIN CALCIUM MARKET SEGMENTATION
- By Type Analysis
As per type, the market is classified into Chemical Synthesis and Biocatalysis.
- By Application Analysis
Based on application, the market is categorized into (Tablet (Including Dispersible Tablet and General Tablet), Capsule, and Others.
DRIVING FACTORS
"Unhealthy Lifestyles and Manufacturing Companies to Facilitate Market Development"
The atorvastatin calcium market is anticipated to be fueled by unhealthy lifestyles, an increase in saturated and trans-fat consumption, and a decrease in physical activity. Another element driving the market is a growth in smoking and alcohol consumption, which increases the chance of having high cholesterol. A highly privatized healthcare system similar to that in the U.S., where pharmaceutical companies offer financial incentives to hospitals to prescribe their prescriptions, is one reason that is expected to contribute to the domination of atorvastatin in India. Manufacturers heavily target doctors and pharmacists when marketing their goods in nations like India.
"Government Support and Kidney Issues to Foster Industry Progress"
The high prevalence of cardiovascular diseases must serve as the primary driver of the atorvastatin calcium market over the predicted time period. Growing dyslipidemia cases in China may pave the way for new avenues of growth for the atorvastatin calcium market. High levels of LDL cholesterol and triglycerides brought on by patients' obesity and inactive lifestyles may help the market.
A large number of kidney issues combined with high dosages of the prescription used by elderly individuals to lower their cholesterol levels can be favorable. Governmental support for large-scale pharmaceutical production may be what propels the growth of the atorvastatin calcium market.
RESTRAINING FACTORS
"Side Effects to Hinder Market Progress "
The following risk factors can raise your chances of suffering more severe or uncommon adverse effects. As with all pharmaceuticals, atorvastatin may have undesirable side effects in some users. There is a chance that you could encounter more serious side effects, even though the majority only experience moderate ones.
ATORVASTATIN CALCIUM MARKET REGIONAL INSIGHTS
"Growing Healthcare Infrastructure to Propel Market Progress in North America"
North America held the largest atorvastatin calcium market share. This is due to strong healthcare infrastructure, a concentration of major industry players, and early adoption of cutting-edge goods.
Asia Pacific is anticipated to have a sizable market share. This is owing to the increased government initiatives, research activity, and public awareness of healthcare in the region.
KEY INDUSTRY PLAYERS
"Incorporation of Research and Development Strategies to Improve their Brand Image"
The report delivers information about the list of market players and their working in the industry. The information is collected and reported with proper research, technological developments, acquisitions, mergers, expanding production lines, and partnerships. Other aspects examined for the global market include companies producing and introducing new products, regions they conduct their operations in, automation, technology adoption, generating the most revenue, and making a difference with their products.
List of Market Players Profiled
- Pfizer (U.S.)
- DSM Sinochem Pharmaceuticals (Netherlands)
- Ind-Swift (India)
- Cadila Pharmaceuticals (India)
- Morepen (India)
- Sun Pharmaceutical Industries (India)
- MSN Laboratories (India)
- Dr. Reddy’s (India)
- Teva Pharmaceutical Industries (Israel)
- Apotex Pharmachem (Canada)
- Zheijang Neo-Dankon Pharmaceutical (China)
- Ningbo Menovo Pharmaceuticals Group (China)
- Jialin Pharmaceutical (China)
- Topfond (China)
- Zhejiang Hisun Pharmaceutical (China)
- Zheijang Hongyuan Pharmaceutical (China)
- Hubei Yitai Pharmaceutical (China)
- Jiangsu Hengrui Medicine (China)
REPORT COVERAGE
The report covers overall market aspects, including the market segmentation based on its type and application. The report depicts a diverse group of participants that includes the market and the potential market leaders. Major factors that are expected to drive major growth in the market. The factors anticipated to expand the market share are also included in the report to offer market insights. The estimated growth of the market in the forecast period is also included in the report. The regional analysis is completed to explain the region's dominance in the global market. The factors hindering the growth of the market are discussed in detail. The SWOT analysis of the market is depicted in the report. It contains all-inclusive market details.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 236.8 Million in 2022 |
Market Size Value By |
US$ 454.06 Million by 2031 |
Growth Rate |
CAGR of 7.5% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type, Application & Region |
Frequently Asked Questions
-
What value is the atorvastatin calcium market expected to touch by 2031?
Based on our research, the atorvastatin calcium market is projected to touch USD 454.06 million by 2031.
-
What CAGR is the atorvastatin calcium market expected to exhibit by 2031?
The atorvastatin calcium market is expected to exhibit a CAGR of 7.5% by 2031.
-
Which are the driving factors of the atorvastatin calcium market?
Government support and unhealthy lifestyle are the factors driving the atorvastatin calcium market.
-
Which are the top companies operating in the atorvastatin calcium market?
Pfizer, DSM Sinochem Pharmaceuticals, Ind-Swift, Cadila Pharmaceuticals, Morepen, Sun Pharmaceutical Industries, MSN Laboratories, Dr. Reddy’s, Teva Pharmaceutical Industries, Apotex Pharmachem, Zheijang Neo-Dankon Pharmaceutical, Ningbo Menovo Pharmaceuticals Group, Jialin Pharmaceutical, Topfond, Zhejiang Hisun Pharmaceutical, Zheijang Hongyuan Pharmaceutical, Hubei Yitai Pharmaceutical, Jiangsu Hengrui Medicine are the top companies operating in the atorvastatin calcium market